請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52986完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李正喆(Jang-Jaer Lee) | |
| dc.contributor.author | Yen-Ching Lee | en |
| dc.contributor.author | 李晏青 | zh_TW |
| dc.date.accessioned | 2021-06-15T16:37:43Z | - |
| dc.date.available | 2020-08-26 | |
| dc.date.copyright | 2020-08-26 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-06 | |
| dc.identifier.citation | [1] Bureau of Health Promotion, Department of Health, Executive Yuan, ROC (Taiwan): Taiwan Osteoporosis Practice Guidelines, 2011 [2] Chestnut C, Majumdar S, Gardner J: Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites, Adv Exp Med Biol 496:95–97, 2001. [3] Cummings S, Martin J, McClung M, Siris E: Denosumab for the prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med 361(8):756–765, 2009. [4] Stopeck A, Body J, Fujiwara Y: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metas¬tases: results of a randomized phase 3 study, Eur J Cancer Suppl 7(2), 2009. [5] Fizazi K, Carducci M, Smith M, et al.: Denosumab versus zole¬dronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study, Lancet 377:813–822, 2011. [6] Henry D, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol 29:1125-1132, 2011. [7] Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938-1956. [8] Paul D. Miller: Denosumab: Anti-RANKL antibody. Current Osteoporosis Reports. 2009; 718-22. [9] Stopeck A, Body J, Fujiwara Y: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metas¬tases: results of a randomized phase 3 study, Eur J Cancer Suppl 7(2), 2009. [10] Diz P, Lopez-Cedrun J, Arenaz J, Scully C: Denosumab-related osteonecrosis of the jaw, J Am Dent Assoc 143(9):981–984, 2012. [11] Prolia® (denosumab) prescribing information, Amgen [12] Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004;351:1860-73. [13] International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57. [14] Takaakichou. Multiple myeloma: recent progress in diag¬nosis and treatment. J Clin ExpHematopathol 52(3): 149- 159, 2012. [15] Greipp P.R, Miguel J.S, Brian G.M., et al: International Staging System for Multiple Myeloma. J ClinOncol 23:3412-3420. [16] Rajkumar SV. Determination of initial therapy in patients with multiple myeloma. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on May 31, 2014.) [17] Mateos MV, Paul GR, Rudolf Schlag., et.al: Bortezomib Plus Melphalan and Prednisone Compared With Mel¬phalan and Prednisone in Previously UntreatedMultiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the PhaseIII VISTA Trial. J Clin Oncol.2010 May 1;28(13):2259-66. [18] Kenneth C. Anderson: Progress and Paradigms in Multiple Myeloma. Clin Cancer Res 2016;22:5419-5427. [19] Kostas Zervas, Evgenia Verrou, Zisis Teleioudis, et al: Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134, 620–623. [20] Marzena Kamińska, Tomasz Ciszewski, Karolina Łopacka-Szatan, et al: Breast cancer risk factors. Prz Menopauzalny, 14 (3) (2015), pp. 196-202. [21] James A. Hanley, et al: Mortality reductions due to mammography screening: Contemporary population-based data. PLoS One. 2017; 12(12): e0188947. [22] Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S. Jeruss: Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 2018 Jan; 27(1): 95–120. [23] Porter, Michael E., Jennifer F Baron, and C. Jason Wang. 'Koo Foundation Sun Yat-Sen Cancer Center: Breast Cancer Care in Taiwan.' Harvard Business School Case 710-425, December 2009. (Revised May 2012.) [24] Ozlem Yersal, Sabri Barutca: Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014 Aug 10; 5(3): 412–424. [25] Wenjing Chen, Andrew D. Hoffmann, Huiping Liu, et al: Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Oncology volume 2, Article number: 4 (2018). [26] Hormone therapy for breast cancer. American Cancer Society. September 18, 2019. [27] Larry D. Sasicha, Sana Rikabi Sukkari: The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm J. 2012 Oct; 20(4): 381–385. [28] Target therapy for breast cancer. American Cancer Society. December 23, 2019 [29] Chemotherapy for breast cancer. American Cancer Society. September 18, 2019 [30] McGuire A1, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015 Mar;34(1):145-55. [31] Hagberg KW1, Taylor A, Hernandez RK, et al: Incidence of bone metastases in breast cancer patients in the United Kingdom: Results of a multi-database linkage study using the general practice research database. Cancer Epidemiology 2013; 37: 240–6. [32] McCartan DP, et al: Role of bone scan in addition to CT in patients with breast cancer selected for systemic staging. Br J Surg 2016; 103: 839–44. [33] Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10;28(35):5132-9. [34] MH Wong, N Pavlakis: Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press). 2011; 3: 35–60. [35] Website of Health Promotion Administration. Ministry of Health and Welfare. [36] Fukagai T., Shimada M., Yoshida H., et al: Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan. Int J Androl. 2000;23 Suppl 2:43-4. [37] Fred Saad, and Sebastien J. Hotte: Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010 Dec; 4(6): 380–384. [38] Treatment for prostate cancer. American Cancer Society. August 1, 2019. [39] Clinical guidelines of prostate cancer 2010. Taiwan Cooperative Oncoloy Group (TCOG). National Health Research Institutes (NHRI). [40] Dillioglugil O, Miles BJ, Scardino PT. Current controversies in the management of localized prostate cancer. Eur Urol 1995; 28:85-101. [41] Gervasi LA, Mata J, Easley JD, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142(2 Pt 1):332-6. [42] Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20. [43] Tannock IF, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12. [44] Lin CC, Hsu CH, Hour TC, et al. Weekly paclitaxel and high dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. Urol Oncol 2007; 25:207-13. [45] De Bono JS, et al.:Horizon scanning for novel therapeutics for the treatment of prostate cancerJ Clin Oncol 28:7s, 2010. [46] Karim Fizazi, NamPhuong Tran, Luis Fein, et al: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377:352-360. [47] Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:25-33. [48] Bianco FJ Jr., Scardino PT, and Eastham JA, Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology, 2005. 66(5 Suppl): p. 83-94. [49] Norgaard, M., et al., Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol, 2010. 184(1): p. 162-7. [50] Tombal, B. and F. Lecouvet, Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? Adv Urol, 2012. 2012: p. 893193. [51] Sarah H. Landis, Taylor Murray, Sherry Bolden, et al: Cancer statistics. CA Cancer J Clin 1999;49: 8-29. [52] Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8. [53] Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate canceL J Am Med Assoe 1998; 280: 975-80. [54] Karim Fizazi, Michael Carducci, Matthew Smith, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–22. [55] Smith MR, Halabi S, Ryan CJ, et al: Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10;32(11):1143-50. [56] Wirth M., Tammela T., Cicalese V., et al: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2015 Mar;67(3):482-91 [57] The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365:395-409. [58] Signs and Symptoms of Lung Cancer. American Cancer Society. October 1, 2019. [59] Tests for Lung Cancer. American Cancer Society. October 1, 2019. [60] The Washington manual of medical therapeutics. 34th edition. [61] Pignon J. , Tribodet H., Scagliotti G., et al: Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9. [62] Hanna N., Bunn PA Jr, Langer C., et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1; 24(13):2038-43. [63] Loïc Lang-Lazdunski : Surgery for nonsmall cell lung cancer. European Respiratory Review 2013 22: 382-404. [64] A. Maciejczyk, I. Skrzypczyńska, and M. Janiszewskab: Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends. Rep Pract Oncol Radiother. 2014 Nov; 19(6): 353–360. [65] Tony S. Mok, Yi-Long Wu, S. Thongprasert., et al: Gefitinib or Carboplatin – Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009; 361:947-957 [66] Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, et al: Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. N Engl J Med 2010; 363:1693-1703. [67] Park J.Y., Kim K.Y., Lee J., et al: Impact of abnormal uptakes in bone scan on the prognosis of patients with lung cancer. Lung Cancer 2000; 28: 55-62. [68] Lung Cancer: Clinical Diagnosis and Treatment, 2nd edn. Grune and Stratton: New York, 1982: 185-200 [69] Henry D., Vadhan-Raj S., Hirsh V., et al: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar;22(3):679-87. [70] Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938-1956. [71] Ruggiero SL, Kohn N.: Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S94-S100. [72] Mücke T, Koschinski J, Deppe H, et al: Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol. 2011 May;137(5):907-13. [73] Wutzl A, Pohl S, Sulzbacher I, et al: Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2012 Feb;34(2):194-200. [74] Yamada S, Kurita H, Kondo E, et al: Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. Clin Oral Investig. 2019 Aug;23(8):3203-3211. [75] Saad F, Brown JE, Van Poznak C, et al: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012 May;23(5):1341-7. [76] Lee JJ, Cheng SJ, Wang JJ, et al: Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study. Head Neck. 2013 Dec;35(12):1787-95. [77] Gosain A, DiPietro LA: Aging and Wound Healing. World J. Surg. 28, 321–326, 2004. [78] Van den Wyngaert T, Claeys T, Huizing MT, et al: Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Annals of Oncology 20: 331–336, 2009. [79] Heughan C, Grislis G, Hunt TK, et al: The effect of anemia on wound healing. Ann Surg. 1974 Feb; 179(2): 163–167. [80] Wright J, Richards T, Srai S :The role of iron in the skin and cutaneous wound healing. Front Pharmacol. 2014; 5: 156. [81] Makoto Kajizono, Hikaru Sada, Yuhko Sugiura, et al: Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. Biol. Pharm. Bull. 38, 1850–1855 (2015). [82] Greenhalt DG. Wound healing and diabetes mellitus. Clinics in Plastic Surgery, 01 Jan 2003, 30(1):37-45. [83] Harold Brem, Marjana Tomic-Canic. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219-1222. [84] Pieper B, Sickon K: Hepatitis C Virus: Patients' risk factors and knowledge in an urban clinic providing wound care. Wounds. 2018 Mar; 30(3):62-67. [85] Kean J. The effects of smoking on the wound healing process. Journal of Wound Care 2009. Vol. 19, No. 1. [86] Silverstein P. Smoking and wound healing. The American Journal of Medicine. July 15, 1992, Volume 93. [87] Wicke C, Halliday B, Allen D, et al: Effects of steroids and retinoids on wound healing. Arch Surg. 2000;135(11):1265-1270. [88] De Santis M, Saad F: Practical Guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology Volume 96, October 2016, Pages 156-164. [89] Purshouse K, Protheroe A: Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. Ther Adv Urol 2019, Vol. 11: 1–8. [90] Raje N, Terpos E, Willenbacher W, et al:Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. Mar;19(3):370-381, 2018. [91] Bonde M, Qvist P, Fledelius C, et al. 1994. Immunoassay for Quantifying Type I Collagen Degradation Products in Urine Evaluated. Clin Chem. 40(11):2022-2025. [92] Salgueiro M, Stribos M, Zhang LF, et al: Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA Journal (2019) 10:21–29. [93] Awad ME, Sun C, Jernigan J, et al: Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy. JADA 2019:150(8):664-675. [94] Stanton D, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 67:943-950, 2009. [95] Favia G, Tempesta A, Limongelli L, et al: Medication-related osteonecrosis of the jaw: Surgical or nonsurgical treatment? Oral Diseases. 2018;24:238–242. [96] Coropciuc RG, Grisar K, Aerden T, et al: Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: Conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg, 2017, Oct;55(8):787-792. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52986 | - |
| dc.description.abstract | 本研究的主要目的，是探討癌症骨轉移患者，使用兩種不同的抗骨吸收藥物（卓骨祂和癌骨瓦），產生顎骨壞死併發症之預後因子。回溯了225個在台大醫院治療顎骨壞死併發症病灶的癌症骨轉移患者，總共299個病灶，利用統計方法分析其治療結果和影響預後的相關因子。完全癒合比率是採用存活分析中的Kaplan-Meier曲線計算，顯著與否則以Log-rank test和Breslow test標示；Cox單變數及多變數分析則用來探討相關的預後因子。所有299個病灶在治療12個月時的累積完全癒合比率為45.4%，其中使用卓骨祂者為42.2%，使用癌骨瓦者為58.2%。性別、病灶部位、類固醇使用、抗骨吸收藥物種類、用藥時間長短、血中骨膠原蛋白碳末端肽鏈數值以及癌症類別等因素，在Cox多變數分析中是顯著影響預後的因子。除了整體299個病灶一同分析之外，也將同樣的統計方式，依不同癌症類別，分開作分析。整體而言，和使用卓骨祂的病灶相比，使用癌骨瓦的病灶，有較佳的預後。 | zh_TW |
| dc.description.abstract | The aim of this study is to find out the prognosis of medication-related osteonecrosis of the jaws（MRONJ） in metastatic cancer patients who received two different type of antiresorptive agents for bone metastasis. We retrospectively surveyed 225 metastatic cancer patients with 299 MRONJ lesions treated in National Taiwan University Hospital. Treatment outcomes and prognostic factors were investigated. The cumulative complete response rate was calculated with the Kaplan-Meier method, and significance was examined with the Log-rank and Breslow tests. Cox regression was used for univariate and multivariate analysis of prognostic factors. The cumulative complete response rate of all 299 lesions at 12 months was 45.4%, and that of patients treated with zolendronic acid and denosumab were 42.2% and 58.2%, respectively. Gender, lesion site, steroid usage, drug type, drug duration, CTX level, and cancer type were prognostic factors in a multivariate analysis. We also carried out the same analysis in individual cancer groups. Compared to zolendronic acid（Zometa）, using denosumab（Xgeva） as the antiresorptive agent indicate a better treatment outcome of MRONJ in metastatic cancer patients. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T16:37:43Z (GMT). No. of bitstreams: 1 U0001-0508202016134900.pdf: 17521475 bytes, checksum: 99faff6f09084bc8ea4a324a1db06bbb (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 誌謝 i 中文摘要 ii ABSTRACT iii 目錄 iv 圖目錄 x 表目錄 xiii 第一章 導論及文獻回顧 1 1.1 本章概要 1 1.2 藥物引起之顎骨壞死併發症 1 1.2.1 骨質疏鬆症 1 1.2.2 癌症患者之骨頭轉移 1 1.2.3 雙磷酸鹽類藥物與顎骨壞死併發症 2 1.2.4 RANKL單株抗體製劑 3 1.3 多發性骨髓瘤 3 1.3.1 多發性骨髓瘤之簡介與分期 3 1.3.2 多發性骨髓瘤之治療與預後 4 1.3.3 多發性骨髓瘤之治療藥物與顎骨壞死併發症之關係 6 1.4 乳癌 7 1.4.1 乳癌之簡介與分期 7 1.4.2 乳癌之治療與預後 8 1.4.3 乳癌骨轉移之治療藥物與顎骨壞死併發症之關係 10 1.5 前列腺癌 11 1.5.1 前列腺癌之簡介與分期 11 1.5.2 前列腺癌之治療與預後 12 1.5.3 前列腺癌骨轉移之治療藥物與顎骨壞死併發症之關係 15 1.6 肺癌 16 1.6.1 肺癌之簡介與分期 16 1.6.2 肺癌之治療與預後 17 1.6.3 肺癌骨轉移之治療藥物與顎骨壞死併發症之關係 20 1.7 藥物引起之顎骨壞死併發症之治療及預後 21 第二章 實驗設計與方法 23 2.1 本章概要 23 2.2 研究目的 23 2.3 樣本與資料蒐集 23 2.3.1 樣本 23 2.3.2 資料蒐集 24 2.4 樣本排除 26 2.5 分組方式 26 2.6 編碼定義 26 2.7 統計方法 27 第三章 實驗結果 29 3.1 本章概要 29 3.2 所有病灶組 29 3.2.1 所有病灶組的描述性資料 29 3.2.2 所有病灶組的治療結果分析 30 3.2.3 所有病灶組和下顎骨截斷術組的描述性資料 30 3.2.4 所有病灶組的預後因子分析 31 3.2.5 所有病灶組中卓骨祂組和癌骨瓦組的描述性資料 35 3.2.6 所有病灶組中卓骨祂組和癌骨瓦組的治療結果分析 37 3.2.7 所有病灶組中卓骨祂組的預後因子分析 37 3.2.8 所有病灶組中癌骨瓦組的預後因子分析 41 3.2.9 所有病灶組的預後因子總整理 45 3.3 多發性骨髓瘤組 45 3.3.1 多發性骨髓瘤組的描述性資料 45 3.3.2 多發性骨髓瘤組的治療結果分析 46 3.3.3 多發性骨髓瘤組和下顎骨截斷術組的描述性資料 46 3.3.4 多發性骨髓瘤組的預後因子分析 47 3.4 乳癌組 50 3.4.1 乳癌組的描述性資料 50 3.4.2 乳癌組的治療結果分析 51 3.4.3 乳癌組和下顎骨截斷術組的描述性資料 51 3.4.4 乳癌組的預後因子分析 52 3.4.5 乳癌組中卓骨祂組和癌骨瓦組的描述性資料 55 3.4.6 乳癌組中卓骨祂組和癌骨瓦組的治療結果分析 57 3.5 前列腺癌組 58 3.5.1 前列腺癌組的描述性資料 58 3.5.2 前列腺癌組治療結果分析 59 3.5.3 前列腺癌組和下顎骨截斷術組的描述性資料 59 3.5.4 前列腺癌組的預後因子分析 60 3.5.5 前列腺癌組中卓骨祂和癌骨瓦組的描述性資料 63 3.5.6 前列腺癌組中卓骨祂組和癌骨瓦組的治療結果分析 64 3.5.7 前列腺癌組中卓骨祂組的預後因子分析 65 3.5.8 前列腺癌組中癌骨瓦組的預後因子分析 68 3.5.9 前列腺癌組的預後因子總整理 70 3.6 肺癌組 70 3.6.1 肺癌組的描述性資料 70 3.6.2 肺癌組的治療結果分析 71 3.7 乳癌合併前列腺癌組 71 3.7.1 乳癌合併前列腺組的描述性資料 72 3.7.2 乳癌合併前列腺癌組的治療結果分析 72 3.7.3 乳癌合併前列腺癌組和下顎骨截斷術組的描述性資料 73 3.7.4 乳癌合併前列腺癌組預後因子分析 73 3.7.5 乳癌合併前列腺癌組中卓骨祂組和癌骨瓦組的描述性資料 77 3.7.6 乳癌合併前列腺癌組中卓骨祂組和癌骨瓦組的治療結果分析 79 3.7.7 乳癌合併前列腺癌中卓骨祂組的預後因子分析 80 3.7.8 乳癌合併前列腺癌組中癌骨瓦組的預後因子分析 83 3.7.9 乳癌合併前列腺癌組的預後因子總整理 86 第四章 實驗討論 87 4.1 本章摘要 87 4.2 性別 87 4.3 年齡 88 4.4 病灶部位 89 4.5 病灶長度和病灶深度 90 4.6 觸發事件 90 4.7 病灶分期 90 4.8 貧血 91 4.9 糖尿病 92 4.10 肝炎 93 4.11 吸菸 94 4.12 類固醇藥物 94 4.13 抗骨吸收藥物種類 95 4.14 抗骨吸收藥物使用時間 98 4.15 血中骨膠原蛋白碳末端肽鏈數值 99 4.16 病灶是否接收手術治療 100 4.17 癌症類別 101 4.18 研究限制和未來工作 102 參考文獻 103 圖 108 表 138 附錄 170 | |
| dc.language.iso | zh-TW | |
| dc.subject | 癌症骨轉移 | zh_TW |
| dc.subject | 顎骨壞死併發症 | zh_TW |
| dc.subject | 卓骨祂 | zh_TW |
| dc.subject | 癌骨瓦 | zh_TW |
| dc.subject | 預後因子 | zh_TW |
| dc.subject | Bone metastasis | en |
| dc.subject | medication-related osteonecrosis of the jaws | en |
| dc.subject | zolendronic acid | en |
| dc.subject | denosumab | en |
| dc.subject | prognostic factors | en |
| dc.title | 癌症骨骼轉移及多發性骨髓瘤患者藥物相關顎骨壞死併發症之預後因子探討 | zh_TW |
| dc.title | Prognostic Factors of Medication-Related Osteonecrosis of the Jaws in Metastatic Cancer and Multiple Myeloma Patients | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭生興(Sang-Heng Kok),羅文良(Wen-Liang Lo) | |
| dc.subject.keyword | 癌症骨轉移,顎骨壞死併發症,卓骨祂,癌骨瓦,預後因子, | zh_TW |
| dc.subject.keyword | Bone metastasis,medication-related osteonecrosis of the jaws,zolendronic acid,denosumab,prognostic factors, | en |
| dc.relation.page | 184 | |
| dc.identifier.doi | 10.6342/NTU202002478 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床牙醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0508202016134900.pdf 未授權公開取用 | 17.11 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。